The below Parliamentary question was asked by Gordon Marsden on 2016-05-05.
To ask Mr Chancellor of the Exchequer, what assessment he has made of the potential cost of the apprenticeship levy to (a) schools and (b) Multi-Academy Trusts in (i) 2017-18, (ii) 2018-19 and (iii) 2019-20.
Greg Hands
Local authorities, academies and multi academy trusts along with all other employers, ‘will only pay the apprenticeship levy if their company paybill exceeds £3 million.
The below Parliamentary question was asked by Henry Smith on 2016-06-27.
To ask the Secretary of State for Health, what steps his Department is taking to raise public awareness of blood cancer and other cancers for which symptoms can be non-specific and have similarities to other benign conditions.
Jane Ellison
Public Health England’s (PHE) Be Clear on Cancer campaigns are designed to raise the public’s awareness of specific cancer symptoms, encourage people with those symptoms to go to the doctor and diagnose cancer at an earlier stage. These campaigns are delivered by PHE in partnership with the Department and NHS England.
The decision on which cancers should be the focus of ‘Be Clear on Cancer’ campaigns is informed by a steering group, whose members include primary and secondary care clinicians, and key voluntary sector organisations.
A number of factors are taken into account when deciding which campaigns to develop and run, with one of the main criteria being the scope to save lives through earlier diagnosis and whether the cancer has a clear early sign or symptom that the general public can act upon should it arise. There are a number of cancers, including those for which symptoms can be non-specific, which are not covered by ‘Be Clear on Cancer’ specifically.
The below Parliamentary question was asked by Lord Kennedy of Southwark on 2016-09-14.
To ask Her Majesty’s Government what is their latest assessment of the human rights situation in North Korea.
Baroness Anelay of St Johns
The UK is deeply concerned about the appalling human rights situation in the Democratic People’s Republic of Korea (DPRK). The UN Commission of Inquiry report, published in 2014, highlighted the severe and systematic human rights violations perpetrated by the regime on its own people. These include summary executions, torture, lack of judicial process, forced labour and prevention of freedom of expression and religion. There is no evidence that the situation is improving. The UK Government will continue to work closely with partners and through international fora to raise its significant concerns about human rights in the DPRK and press for substantial reforms to improve the lives of North Korean citizens. The UK regularly raises our concerns about human rights violations directly with the regime through our Embassy in Pyongyang. The UK will support the annual resolution on DPRK human rights at the forthcoming UN General Assembly to maintain international attention on that country’s dire human rights record. I include with this answer a copy of the Foreign and Commonwealth Office Human Rights Report 2015 which includes a fuller assessment of the human rights situation in the DPRK.
The below Parliamentary question was asked by Ian Murray on 2015-11-10.
To ask the Secretary of State for Scotland, what discussions he had with women’s organisations in Scotland prior to his proposal to devolve responsibility for abortion legislation to the Scottish Parliament.
David Mundell
The Smith Commission considered the issue of the devolution of abortion carefully and was ‘strongly of the view to recommend the devolution of abortion’ and regarded it as an ‘anomalous health reservation.’ The Smith Agreement said that ‘further serious consideration should be given to its devolution and a process should be established immediately to consider the matter further.’ That process took place between the UK and Scottish Governments and resulted in an amendment to the Scotland Bill to devolve responsibility for abortion law to the Scottish Parliament. Since laying that amendment the Government has been engaging with interested parties about how the process of devolution will work and it will be for the Scottish Government to set out what approach it will take once responsibility for abortion law rests with the Scottish Parliament. The 1967 Act will continue to apply in Scotland unless and until the Scottish Parliament chooses to legislate in this area, and the First Minister recently confirmed that the Scottish Government have no plans to do so.
The below Parliamentary question was asked by Jim Shannon on 2015-12-09.
To ask the Secretary of State for Foreign and Commonwealth Affairs, what support the UK has provided to interfaith peace-building initiatives in Nigeria; and what assessment he has made of the outcomes of such initiatives.
James Duddridge
We recognise the important role that interfaith understanding has to play in peace building in Nigeria.
The Department for International Development (DFID) supports a range of initiatives and economic projects to build bridges between Muslim and Christian communities across Nigeria and break the cycle of conflict. For example, through DFID’s Stability and Reconciliation Programme (NSRP) religious, traditional and community leaders meet monthly with NGOs, the police, security services and civil society actors to discuss and act on conflict issues.
The below Parliamentary question was asked by Baroness Armstrong of Hill Top on 2016-01-19.
To ask Her Majesty’s Government how much the Homes and Communities Agency awarded in (1) 2012–13, (2) 2013–14, and (3) 2014–15 to the Empty Homes programme.
Baroness Williams of Trafford
The Homes and Community Agency made available £110.6 million to bring empty homes back into use over two rounds of funding:
The Homes and Community Agency’s Affordable Homes Programme will continue to provide funding to bring empty homes back into use. The Affordable Homes Programme is a competitive scheme and the amount of funding allocated to empty homes will depend on the quality of the bids received.
The below Parliamentary question was asked by Steve McCabe on 2016-02-11.
To ask the Secretary of State for Health, what changes his Department plans to pharmacy funding; and what assessment his Department has made of the effect of those changes on small independent businesses.
Alistair Burt
Community pharmacy is a vital part of the National Health Service and can play an even greater role. In the Spending Review the Government re-affirmed the need for the NHS to deliver £22 billion in efficiency savings by 2020/21 as set out in the NHS’s own plan, the Five Year Forward View. Community pharmacy is a core part of NHS primary care and has an important contribution to make as the NHS rises to these challenges. The Government believes efficiencies can be made without compromising the quality of services including public access to medicines. Our aim is to ensure that those community pharmacies upon which people depend continue to thrive and so we are consulting on the introduction of a Pharmacy Access Scheme, which will provide more NHS funds to certain pharmacies compared to others, considering factors such as location and the health needs of the local population.
Our proposals are about improving services for patients and the public and securing efficiencies and savings. A consequence may be the closure of some pharmacies but that is not our aim.
The below Parliamentary question was asked by Roger Godsiff on 2016-03-03.
To ask the Secretary of State for Health, pursuant to the Answer of 24 February 2016 to Question 28215, what the implications for the availability of Sativex to Multiple Sclerosis patients are of the NICE guidance that Sativex is not recommended as a treatment option.
George Freeman
The National Institute for Health and Care Excellence’s (NICE) clinical guideline on the management of multiple sclerosis, published in October 2014, does not recommend Sativex as a cost effective use of National Health Service resources.
In the absence of positive guidance from NICE, it is for commissioners to make decisions on whether to fund this treatment based on an assessment of the available evidence.
The below Parliamentary question was asked by Lord Moynihan on 2016-04-12.
To ask Her Majesty’s Government, in the light of the publication in SLEEP on 1 February of the epidemiological study into the association between the 2009 pandemic H1N1 vaccine and narcolepsy in adults (Pub Med identifier 26856903), whether the Department for Work and Pensions will now reverse its decisions to refuse applications for compensation for adults under the Vaccine Damage Payments Act 1979 on the grounds of a lack of evidence of causation, and if not, on what basis they continue to dispute causation for adults.
Baroness Altmann
All claims under the Vaccine Damage Payment Scheme are decided on the basis of each claimant’s individual circumstances, and in light of the latest scientific evidence on the possible effects of vaccines. The Department monitors research in this area. We are aware of the latest evidence and are studying it carefully. Where new evidence comes to light which suggests that an earlier decision was incorrect, the claimant may ask the Department to look at its decision again within the statutory time limits.
The below Parliamentary question was asked by Cat Smith on 2016-05-05.
To ask the Secretary of State for Health, what steps he is taking to ensure that (a) clinical commissioning groups and (b) pharmacists are made aware of the Medicines and Healthcare products Regulatory Agency toolkit on the risks of valproate medicines in female patients.
George Freeman
Valproate is an effective treatment for epilepsy and bipolar disorder but should only be used in girls and women of childbearing potential if other treatments are ineffective or not tolerated. For some women there may be no other treatment option. Since it was authorised, valproate was known to have risks in pregnancy. Because of ongoing concerns about women’s awareness of the risks, the Medicines and Healthcare products Regulatory Agency (MHRA) has worked with professional bodies, voluntary organisations and patient groups to develop a set of materials to aid communication between health professionals and women and girls.
The valproate toolkit comprises booklets for healthcare professionals, a reminder card and a guide for women, a checklist for prescribers and clear package labelling carrying a prominent warning about use in pregnancy. It was widely disseminated on 8 February 2016 through a Central Alerting System (a web based cascade system for issuing alerts to the National Health Service) and the MHRA’s Drug Safety Update bulletin. Electronic copies of the toolkit are hosted on several websites including the Electronic Medicines Compendium. Letters and hard copies of the toolkit were sent by the marketing authorisation holder directly to general practitioners (GPs), pharmacists and relevant specialists. This included 400,000 patient cards, 81,000 patient guides and 22,000 healthcare professional booklets.
In order to monitor the effectiveness of the valproate toolkit, the MHRA has sought feedback from all stakeholders and will continue to work with the Royal Colleges, professional bodies including the Royal Pharmaceutical Society, patient groups and relevant charities to increase awareness of the toolkit among GPs, pharmacists and patients.This work will include exploring how clinical commissioning groups can help ensure the toolkit materials are being used.
So far, the MHRA has worked with voluntary organisations and patient groups to produce online patient surveys to measure awareness of the risks among patients. Furthermore, MHRA is conducting a study using the Clinical Practice Research Datalink to track changes in prescribing of valproate to women and girls following the communications to healthcare professionals and patients on the risks of valproate in pregnancy. The marketing authorisation holder is conducting Europe-wide studies to measure the changes in patterns of prescribing and awareness of the healthcare professionals of the risks. The available data will be brought together in a regularly updated dashboard that will be used to track the impact of the communications on patient and professional awareness over time.
The Government has great sympathy for those families who have been affected by the use of valproate in pregnancy. There is support available for families with children born with a disability. For many people this will involve an early intervention programme from health visitors and midwives, to help a child develop, as well as provide support to the family. This might include: speech and language therapy – to help with any problems communicating or feeding; physiotherapy – to help with any muscle weakness or movement difficulties, and individual home teaching programmes.
Where a child has a special educational need the local authority must make support available to ensure the child had access to the same educational opportunities as a child without such a need. The Children and Families Act 2014 introduced a new statutory framework for local authorities and to work together to secure services for children and young people – up to the age of 25 – who have special educational needs or disability, across education, health and social care.
The MHRA’s current priority is to work to ensure that women taking valproate are fully aware of the risks in pregnancy. Once this is achieved we will look into the history of the episode and see what lessons have been or could be usefully learnt by examining events.